6NOU
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6nou by Molmil](/molmil-images/mine/6nou) | An scFv derived from ixekizumab | Descriptor: | GLYCEROL, scFv derived from ixekizumab | Authors: | Durbin, J.D, Clawson, D.K, Lu, F, Tian, Y, Lu, J, Atwell, S. | Deposit date: | 2019-01-16 | Release date: | 2019-06-19 | Last modified: | 2019-08-14 | Method: | X-RAY DIFFRACTION (1.914 Å) | Cite: | Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. Mabs, 11, 2019
|
|
6NOV
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6nov by Molmil](/molmil-images/mine/6nov) | A Fab derived from ixekizumab | Descriptor: | DODECAETHYLENE GLYCOL, Fab Heavy Chain, Fab Light Chain | Authors: | Durbin, J.D, Clawson, D.K, Lu, F, Tian, Y, Lu, J, Schmitt, M, Atwell, S. | Deposit date: | 2019-01-16 | Release date: | 2019-06-19 | Last modified: | 2019-08-14 | Method: | X-RAY DIFFRACTION (2.14 Å) | Cite: | Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. Mabs, 11, 2019
|
|